The critical need to develop new antibiotics has been underlined by the Association of the British Pharmaceutical Industry (ABPI).
In an age when drug resistant microbes are developing faster than new antimicrobial treatments, the UK’s pharma trade association has issued a rallying call to governments, healthcare workers and pharma companies around the world to do more to avoid the threat posed by antibiotic resistance.
"Antibiotic resistance is a silent threat to the very foundations of modern medicine"They can do this by coming together to protect existing antimicrobial treatments and collaborate at a global level to develop sustainable long-term solutions for discovering new treatments and bringing these to patients, according to the ABPI.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze